Please click on the ID to see detailed information about each entry.
The total number entries retrieved from this search are| ID | Sequence | Name | Nature of peptide or cargo | Assay | Tissue permeability | Tissue Sample | PUBMED ID |
|---|---|---|---|---|---|---|---|
| 1043 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | >5% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1044 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~6% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1045 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~1.5% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1046 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~5% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1047 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~3% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1048 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~2% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1049 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~7% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1050 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~3% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1051 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 2% of applied dose | Stratum corneum of human breast skin | 22890441 |
| 1052 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~11% of applied dose | Epidermis of human breast skin | 22890441 |
| 1053 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~9% of applied dose | Epidermis of human breast skin | 22890441 |
| 1054 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~3% of applied dose | Epidermis of human breast skin | 22890441 |
| 1055 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~10% of applied dose | Epidermis of human breast skin | 22890441 |
| 1056 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~7% of applied dose | Epidermis of human breast skin | 22890441 |
| 1057 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~5% of applied dose | Epidermis of human breast skin | 22890441 |
| 1058 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~12% of applied dose | Epidermis of human breast skin | 22890441 |
| 1059 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | >4% of applied dose | Epidermis of human breast skin | 22890441 |
| 1060 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~4% of applied dose | Epidermis of human breast skin | 22890441 |
| 1061 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | >36% of applied dose | Dermis of human breast skin | 22890441 |
| 1062 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | >26% of applied dose | Dermis of human breast skin | 22890441 |
| 1063 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~26% of applied dose | Dermis of human breast skin | 22890441 |
| 1064 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 25% of applied dose | Dermis of human breast skin | 22890441 |
| 1065 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 20% of applied dose | Dermis of human breast skin | 22890441 |
| 1066 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~20% of applied dose | Dermis of human breast skin | 22890441 |
| 1067 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~26% of applied dose | Dermis of human breast skin | 22890441 |
| 1068 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 13% of applied dose | Dermis of human breast skin | 22890441 |
| 1069 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 14% of applied dose | Dermis of human breast skin | 22890441 |
| 1070 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 9.5% of applied dose | Acceptor compartment of Franz diffusion cell | 22890441 |
| 1071 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~7% of applied dose | Acceptor compartment of Franz diffusion cell | 22890441 |
| 1072 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | >19% of applied dose | Acceptor compartment of Franz diffusion cell | 22890441 |
| 1073 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | 21% of applied dose | Acceptor compartment of Franz diffusion cell | 22890441 |
| 1074 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | >8% of applied dose | Acceptor compartment of Franz diffusion cell | 22890441 |
| 1075 | β-Ala-H | N-acetyl- L -carnosine | Antioxidant | Franz diffusion cell, HPLC | ~15% of applied dose | Acceptor compartment of Franz diffusion cell | 22890441 |
| 1110 | YTSLIHSLIEESQNQQ EKNEQELLELDKWAS LWNWF | N-acetylated T20 | Fusion inhibitor | Real-time PCR | IC50 of 51.2 microM (230 ng/ml; 95% confidence interval, 198 to 267 ng/ml; n 8 independent experiments with 4 donor tissues) | Vaginal epithelial sheet | 19949052 |
| 1289 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 57% (32 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1290 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 55% (23 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1291 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 54% (21 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1292 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 56% (20 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1293 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 58% (16 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1294 | GrGDIPASSKGGGGS rLLLLLLr | RGD peptide matrix | Acts as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer site | At each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done. | Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 61% (14 patients) | Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle | 8080985 |
| 1301 | SYSMEHFRWGKPV | α-Melanocyte stimulating hormone (MSH) | Controls pigmentary changes in many vertebrates and melanin synthesis within epidermal melanocytes is responsible for melanin pigmentation of the skin, hair, and feathers in man, birds and other mammals. | Light and electron microscopy | 10-7 and 10-8 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1302 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone | Light and electron microscopy | 10-7 to 10-12 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1303 | Nle-EHfRWGK | [Nle4, D-Phe7]-alpha-MSH4-11 | Not mentioned | Light and electron microscopy | 10-8 to 10-14 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1304 | Nle-EHfRWG | [Nle4, D-Phe7]-alpha-MSH4-10 | Not mentioned | Light and electron microscopy | 10-8 to 10-14 concentrations turned yellow hair brown | Melanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect | 3684299 |
| 1306 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7]-α-MSH | the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of mice | Electron microscopy and Light microscopy | Concentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application. | dorsal trunk of mice (C57BL/6JA y) | 3624899 |
| 1307 | Nle-EHfFRWGK | Ac-[Nle4, D-Phe7]-α- MSH4–11-NH2 | the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of mice | Electron microscopy and Light microscopy | Concentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application. | dorsal trunk of mice (C57BL/6JA y) | 3624899 |
| 1308 | Nle-EH-FRWG | Ac-[Nle4, D-Phe7]-α-MSH4–10-NH2 | the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of mice | Electron microscopy and Light microscopy | Concentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application. | dorsal trunk of mice (C57BL/6JA y) | 3624899 |
| 1309 | SYSMEHFRWGKPV | α-Melanocyte stimulating hormone (MSH) | Controls pigmentary changes in many vertebrates and melanin synthesis within epidermal melanocytes is responsible for melanin pigmentation of the skin, hair, and feathers in man, birds and other mammals. | Electron microscopic examination | Minimal effective dose=10-8to10-9M. It stimulated eumelanogenesis in all hair emerging from the areas previously plucked. | Posterior dorsum of mice (C57BL/6JA y) | 3573985 |
| 1310 | SYS-Nle-EHfRWGKPV | (Nle4, D-Phe7)-a-MSH | The analogue is superpotent, being 10- 1000 times more active than the native hormone | Electron microscopic examination | Minimal effective dose=10-12M. It is transdermally delivered systemically to hair follicles throughout the body to induce follicular melanogenesis. Microscopic examination revealed eumelanin within hair bulbs by 24 hours after topical application of the analogue. | Posterior dorsum of mice (C57BL/6JA y) | 3573985 |
| 1311 | SYS-Nle-EHfRWGKPV | [Nle4, D-Phe7]-alpha-MSH | A superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes. | Frog Skin Bioassay | Percent positive samples of transdermal delivery :65% (15/23) | Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of either black or yellow adult C57BL/6JAy mice killed by cervical dislocation | 2845208 |